98%
921
2 minutes
20
Background: Malignant peripheral nerve sheath tumor (MPNST) is a kind of rare neurogenic tumor. If associated with neurofibromatosis type 1, MPNST usually has a higher mortality. The aim of the article is to assess the imaging characteristics of MPNST and compare them with those of benign peripheral nerve sheath tumor (BPNST) to characterize this tumor.
Methods: Clinical and imaging data of six cases with MPNST and 28 cases with BPNST in our institution since 2011 were retrospectively reviewed. Thirty-three patients have available MR imaging data, and two patients of MPNST also accepted CT scan. One patient accepted CT scan only. Location, size, shape, signal or density, boundary, bone destruction, relation to adjacent nerve, contrast-enhanced features as well as some other signs were assessed and compared with statistical software. Student's t test was used for comparison of continuous variables. Fisher's exact test was used for analysis of nominal variable. A P value ≤0.05 was considered to be statistically significant.
Results: Differences existed between two groups in tumor size ((7.2 ± 3.3)cm in MPNST vs. (3.8 ± 1.4)cm in BPNST), unclear margin (4/6 in MPNST vs. 1/28 in BPNST), eccentricity to the nerve (1/6 in MPNST vs. 21/28 in BPNST), intratumoral lobulation (4/6 in MPNST vs. 2/28 in BPNST), peritumoral edema (3/6 in MPNST vs. 0 in BPNST), and peripheral enhancement (4/6 in MPNST (three of five MR, one CT) vs. 4/28 in BPNST). Bone destruction was observed in one MPNST.
Conclusions: MR imaging is a valuable, non-invasive modality for the diagnosis of MPNST. Peripheral enhancement with non-cystic appearance or remarkable heterogeneous enhancement may be useful for differential diagnosis. Other imaging features such as large size (over 5 cm in diameter), ill-defined margin, intratumoral lobulation, peritumoral edema, and adjacent bone destruction are also supportive of MPNST.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862189 | PMC |
http://dx.doi.org/10.1186/s12957-016-0899-0 | DOI Listing |
Cancer Diagn Progn
September 2025
Institute of Neuropathology, Eppendorf University Hospital, University of Hamburg, Hamburg, Germany.
Background/aim: Neurofibromatosis type 1 (NF1) is a genetic disorder characterized by the development of multiple tumors, including plexiform neurofibromas (PNFs), which often affect the craniofacial region and cause significant functional and aesthetic impairments. This report presents long-term surgical management of a patient with hemifacial diffuse PNF, complicated by the emergence of a rapidly enlarging midfacial tumor.
Case Report: The patient was treated for hemifacial invasive diffuse plexiform neurofibroma.
J Craniofac Surg
September 2025
Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, P.R. China.
Objective: This study summarized the application effect and clinical experience of multimodal intraoperative neurophysiological monitoring (IONM) technology in the surgery of neurofibromatosis type 1 (NF1)-related craniofacial tumors.
Materials And Methods: A retrospective study was conducted on NF1 patients who were admitted between January 2019 and December 2024 and treated with craniofacial tumor resection surgery assisted by multimodal IONM technology. Data from this study were analyzed regarding sex, age at surgery, surgical procedures, IONM parameters, preoperative and postoperative symptoms, follow-up period, as well as oncological outcome.
Br J Cancer
September 2025
Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan.
Background: Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder characterized by neurofibromas, with 5-13% of patients risk developing malignant peripheral nerve sheath tumors (MPNST). Current treatments for MPNST are largely ineffective. AXL, overexpressed in MPNST, is a potential target for Chimeric Antigen Receptor T (CAR-T) cell therapy.
View Article and Find Full Text PDFInt J Surg Case Rep
August 2025
Plastic and Reconstructive Surgery, Hospital Infantil de México, Federico Gómez, Mexico City, Mexico.
Introduction And Importance: Malignant peripheral nerve sheath tumor (MPNST), also called malignant schwannoma, neurofibrosarcoma and neurogenic sarcoma, is a malignant neoplastic lesion originating in the Schwann cells of the sheath lining of peripheral nerves.
Case Presentation: A 2-year-old, 7-month-old female patient, was admitted to our clinic due to progressive enlargement of the right forearm, physical examination revealed a tumor on the right forearm, painless, fixed to adjacent structures, hard, with erythema and swelling in the upper part of the lesion, complete surgical excision of the tumor with left inguinal graft was performed, covering the entire resected surgical defect. The pathology report was a malignant peripheral nerve sheath tumor.
J Exp Clin Cancer Res
August 2025
Institute of Neuroscience, National Research Council, via Ugo Bassi 58/B, Padova, 35131, Italy.
Background: Metabolic adaptations can sustain the pro-neoplastic functions exerted by macrophages in the tumor microenvironment. Malignant peripheral nerve sheath tumors (MPNSTs), aggressive and incurable sarcomas that develop either sporadically or in the context of the genetic syndrome Neurofibromatosis type 1, are highly infiltrated by macrophages, whose contribution to MPNST growth remains poorly characterized. Here, we analyze the role played by the molecular chaperone TRAP1, a regulator of mitochondrial metabolic pathways, in shaping the pro-tumoral activity of macrophages associated to MPNST cells.
View Article and Find Full Text PDF